Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class III antiarrhythmics changes all‐cause mortality compared with control (very low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: requirement for 1 or more hospitalisations for atrial tachyarrhythmia · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
All‐cause mortality · Human trial participants undergoing ablation for atrial fibrillation
Class I and/or III antiarrhythmics showed no clear difference in all‐cause mortality compared with control (low certainty).
1 finding from 1 review
Outcomes and · adults with arrhythmias undergoing catheter ablation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events · adults with arrhythmias undergoing catheter ablation
It is very uncertain whether interrupted changes thromboembolic events compared with uninterrupted anticoagulation therapy (very low certainty).
1 finding from 1 review
Major bleeding · adults with arrhythmias undergoing catheter ablation
Interrupted showed no clear difference in major bleeding compared with uninterrupted anticoagulation therapy (low certainty).
1 finding from 1 review
Composite endpoint of thromboembolic events (stroke or systemic embolism), major bleeding events, and all‐cause mortality · adults with arrhythmias undergoing catheter ablation
Interrupted may leads to lower composite endpoint of thromboembolic events (stroke or systemic… compared with uninterrupted anticoagulation therapy (low certainty).
1 finding from 1 review
Minor bleeding · adults with arrhythmias undergoing catheter ablation
It is very uncertain whether interrupted changes minor bleeding compared with uninterrupted anticoagulation therapy (very low certainty).
1 finding from 1 review
All‐cause mortality · adults with arrhythmias undergoing catheter ablation
Interrupted showed no clear difference in all‐cause mortality compared with uninterrupted anticoagulation therapy (low certainty).
1 finding from 1 review
Asymptomatic thromboembolic events · adults with arrhythmias undergoing catheter ablation
It is very uncertain whether interrupted changes asymptomatic thromboembolic events compared with uninterrupted anticoagulation therapy (very low certainty).
1 finding from 1 review